Ezetimibe/Simvastatin or Atorvastatin for the Treatment of Hypercholesterolemia in Patients with the Metabolic Syndrome: The VYMET Study

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group [no authors listed]. N Engl J Med 1998, 339:1349–1357. Cannon C, Braunwald E, McCabe C, et al.: Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004, 350:1495–1504. Conard SE, Bays HE, Leiter LA, et al.: Efficacy and safety of ezetimibe added on to atorvastatin (20 mg) versus uptitration of atorvastatin (to 40 mg) in hypercholesterolemic patients at moderately high risk for coronary heart disease. Am J Cardiol 2008, 102:1489–1494. Leiter LA, Bays H, Conard S, et al.: Efficacy and safety of ezetimibe added on to atorvastatin (40 mg) compared with uptitration of atorvastatin (to 80 mg) in hypercholesterolemic patients at high risk of coronary heart disease. Am J Cardiol 2008, 102:1495–1501. Kastelein JJ, Akdim F, Stroes ES, et al.: Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008, 358:1431–1443. Taylor AJ, Villines TC, Stanek EJ, et al.: Extended-release niacin or ezetimibe and carotid intima-thickness. N Engl J Med 2009, 361:2113–2122.